Drugs / MGD009
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03406949 | Feb 2018 → Apr 2022 | neoplasm | MacroGenics | Completed | No outcome recorded |
| Phase 1 | NCT02628535 | Sep 2015 → Nov 2019 | breast cancer, clear cell renal carcinoma, colon carcinoma, head and neck squamous cell carcinoma +9 | MacroGenics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGD009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02628535 ↗ |
| Known as | obrindatamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03406949 ↗ |
| Modality | Protein / enzyme biologic | “Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein” NCT02628535 ↗ |
| Route | Intravenous | “MGD009 administered intravenously (IV) on an every-other-week schedule” NCT02628535 ↗ |